Novartis stock forecast: Third-party projections
Novartis last traded at 98.25 CHF as of 8:54am (UTC) on 30 October 2025, hitting the session high and holding above the intraday low of 96.95 CHF.
Recent Novartis (NOVN) price action reflects ongoing macro and company-specific influences. Novartis reported 7% third-quarter sales growth in constant currency and reiterated its annual guidance, supported by late-stage trial results for its autoimmune drug ianalumab (Novartis, 28 October 2025).
Novartis stock forecast: Analyst price target view
MarketBeat (consensus sample)
MarketBeat reports a 12-month average price target of $120.33, based on estimates from ten analysts. Targets range from $118 to $123. The consensus holds a “hold” rating, reflecting a balanced view following the company’s earnings and pipeline updates amid generic competition and new drug launches (MarketBeat, 25 October 2025).
Benzinga (analyst sample)
Benzinga compiles nine analyst forecasts to set a consensus target of $120.50, with a high of $130 and low of $114. Sources include Goldman Sachs, BMO Capital and BofA Securities, with key drivers cited as trial progress and generic competition (Benzinga, 27 October 2025).
Investing.com (CHF average)
Investing.com’s European analyst consensus puts the 12-month average target at CHF 97.35, with estimates ranging from 77.68 CHF to 115.60 CHF. Divergence reflects views on earnings, FX exposure and operational performance in the Swiss market (Investing.com, 20 July 2025).
Analyst targets for Novartis cluster within $118–$130 and 77–115.60 CHF shaped by new drug activity, upcoming patent expirations and international pricing dynamics.
Analyst forecasts may not be accurate. Past performance is not a reliable indicator of future results.
NOVN stock price: Technical overview
Novartis (NOVN) last traded at CHF 98.25 as of 8:54am (UTC) on 30 October 2025, holding near the Classic Pivot level of 100.26 and tracking within the 96.95–98.25 CHF session range.
The daily chart shows clustered simple moving averages (20/50/100/200-DMAs): ~103.8 / 101.8 / 98.9 / 96.7. Price remains below the short- and medium-term averages, but above the 200-DMA.
Momentum indicators are muted. RSI(14) stands at 31.02, not signalling overbought or oversold conditions. ADX(14) at 25.00 points to a more established trend. Oscillators including MACD and Awesome Oscillator suggest subdued momentum, while the Commodity Channel Index and Williams %R indicate underlying buying interest (TradingView, 30 October 2025).
This is technical analysis for informational purposes only and does not constitute financial advice or a recommendation.
Novartis share price history
Novartis shares have followed a steady path over the past two years. In October 2023, NOVN traded around 84 CHF, gradually rising throughout 2024 as broader markets recovered. The stock crossed 95 CHF in early 2025, supported by company-specific news and sector momentum.
In H2 2025, the stock reached 104 CHF before pulling back to 98.30 CHF by 30 October. Year-to-date, NOVN is down ~2%, but up ~17% from the same time last year—a performance shaped by macro shifts and pharma sector developments.
Past performance is not a reliable indicator of future results.
Past performance is not a reliable indicator of future results.
Capital.com’s client sentiment for Novartis CFDs
As of 30 October 2025, Capital.com clients are 95.9% long on Novartis CFDs, with just 4.1% holding short positions – putting sentiment in heavy-buy territory. This reflects open positions and is subject to change.
FAQ
Is Novartis a good stock to buy?
This depends on individual goals and risk appetite. Analysts tracked by MarketBeat, CFRA, Zacks and others currently hold a consensus ‘hold’ rating, citing balanced expectations around pipeline developments, pricing pressures, and upcoming patent expirations. Past performance is not a reliable indicator of future results.
Could Novartis stock go up or down?
Like any equity, Novartis stock is subject to market forces. Analyst targets range from $108 to $134 and 77.68 CHF to 115.60 CHF, reflecting differing views on its earnings outlook, product pipeline, and exposure to generic risk. Past performance is not a reliable indicator of future results.
Should I invest in Novartis stock?
Capital.com doesn’t provide investment advice. If you're considering Novartis, it’s important to do your own research or speak with an independent financial adviser. Always consider your financial goals and risk profile. Contracts for difference (CFDs)s are traded on margin – leverage amplifies both profits and losses.